Cyclopharm Ltd (ASX: CYC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cyclopharm Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$126.99 million
P/E Ratio
N/A
Dividend Yield
0.76%
Shares Outstanding
93.37 million
Earnings per share
-0.056
Dividend per share
0.01
Year To Date Return
-19.82%
Earnings Yield
N/A
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cyclopharm Ltd (ASX: CYC)
Latest News
Share Gainers
Cyclopharm (ASX:CYC) share price jumps on trading update
Healthcare Shares
Why the Cyclopharm (ASX:CYC) share price is crashing 42% lower
Healthcare Shares
Why is the Cyclopharm (ASX:CYC) share price down today?
Share Market News
Why the Cyclopharm (ASX:CYC) share price popped 6% today
Share Market News
Why the Cyclopharma (ASX:CYC) share price surged to record high today
Speculative
Cyclopharm share price rockets 22% higher on FDA application approval
⏸️ Investing
3 speculative micro-cap shares that could make you a fortune
⏸️ Investing
3 cheap diversified micro-cap stocks for your portfolio
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 04 Apr 2022 | $0.0050 | 0.00% | Final | 12 Apr 2022 |
| 03 Sep 2021 | $0.0050 | 0.00% | Interim | 13 Sep 2021 |
| 01 Apr 2021 | $0.0050 | 0.00% | Final | 13 Apr 2021 |
| 04 Sep 2020 | $0.0050 | 0.00% | Interim | 14 Sep 2020 |
| 30 Mar 2020 | $0.0050 | 0.00% | Final | 07 Apr 2020 |
| 06 Sep 2019 | $0.0050 | 0.00% | Interim | 16 Sep 2019 |
| 05 Apr 2019 | $0.0050 | 0.00% | Final | 15 Apr 2019 |
| 07 Sep 2018 | $0.0050 | 0.00% | Interim | 17 Sep 2018 |
| 06 Apr 2018 | $0.0050 | 0.00% | Final | 16 Apr 2018 |
| 01 Sep 2017 | $0.0050 | 0.00% | Interim | 11 Sep 2017 |
| 31 Mar 2017 | $0.0050 | 0.00% | Final | 10 Apr 2017 |
| 02 Sep 2016 | $0.0050 | 46.00% | Interim | 12 Sep 2016 |
| 11 Apr 2016 | $0.0050 | 100.00% | Interim | 19 Apr 2016 |
| 05 Oct 2015 | $0.0050 | 100.00% | 14 Oct 2015 |
CYC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cyclopharm Ltd
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
CYC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 18 May 2022 | $1.36 | $0.05 | 3.82% | 13,306 | $1.33 | $1.37 | $1.30 |
| 17 May 2022 | $1.31 | $0.00 | 0.00% | 1,500 | $1.31 | $1.31 | $1.31 |
| 16 May 2022 | $1.31 | $0.01 | 0.77% | 7,874 | $1.36 | $1.37 | $1.30 |
| 13 May 2022 | $1.30 | $-0.06 | -4.41% | 44,600 | $1.33 | $1.33 | $1.30 |
| 12 May 2022 | $1.36 | $-0.01 | -0.73% | 3,000 | $1.37 | $1.37 | $1.36 |
| 11 May 2022 | $1.38 | $-0.01 | -0.72% | 1,491,064 | $1.38 | $1.38 | $1.38 |
| 10 May 2022 | $1.39 | $0.00 | 0.00% | 15,705 | $1.37 | $1.39 | $1.37 |
| 09 May 2022 | $1.39 | $0.01 | 0.73% | 17,291 | $1.39 | $1.39 | $1.38 |
| 06 May 2022 | $1.38 | $-0.11 | -7.41% | 97,968 | $1.42 | $1.42 | $1.35 |
| 05 May 2022 | $1.49 | $0.00 | 0.00% | 3,853 | $1.49 | $1.49 | $1.49 |
| 04 May 2022 | $1.49 | $0.01 | 0.68% | 32,785 | $1.48 | $1.49 | $1.42 |
| 03 May 2022 | $1.48 | $-0.03 | -1.99% | 5,538 | $1.49 | $1.49 | $1.48 |
| 02 May 2022 | $1.51 | $0.01 | 0.67% | 10,609 | $1.50 | $1.51 | $1.45 |
| 29 Apr 2022 | $1.50 | $-0.01 | -0.66% | 8,800 | $1.51 | $1.51 | $1.50 |
| 28 Apr 2022 | $1.51 | $0.01 | 0.67% | 34,438 | $1.51 | $1.52 | $1.51 |
| 27 Apr 2022 | $1.50 | $-0.01 | -0.66% | 10,001 | $1.50 | $1.50 | $1.47 |
| 26 Apr 2022 | $1.51 | $-0.01 | -0.66% | 27,882 | $1.53 | $1.53 | $1.50 |
| 22 Apr 2022 | $1.53 | $0.02 | 1.33% | 35,956 | $1.53 | $1.53 | $1.45 |
| 21 Apr 2022 | $1.50 | $-0.05 | -3.23% | 15,135 | $1.55 | $1.55 | $1.50 |
| 20 Apr 2022 | $1.55 | $0.05 | 3.33% | 22,319 | $1.52 | $1.56 | $1.52 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 09 Mar 2022 | David Heaney | Buy | 10 | $14,855 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr David James Heaney | Non-Executive DirectorNon-Executive Chairman | Nov 2006 |
Mr Heaney has more than 40 years experience in all aspects of wholesale banking and finance, gained in senior management roles with National Australia Bank Limited and subsidiary companies in both Australia and the US. He served as a non-executive director of Colorpak Limited from February 2004 until May 2016 and has also previously been a non-executive director of other listed and non-listed companies. He is Chair of the Risk committee.
|
| Ms Dianne Margaret Angus | Non-Executive Director | Aug 2021 |
Ms Angus has experience working as an executive and a Director in the Biotechnology industry including with Prana Biotechnology Limited (now Alterity Therapeutics) and Florigene Limited. Dianne also has experience in corporate strategy, innovative product development, governance and compliance in our sector. She is also a Non-Executive Director of ASX Listed Companies Imagion Biosystems Limited and Neuren Pharmaceuticals Limited.
|
| Mr James S McBrayer | Chief Executive OfficerManaging DirectorCompany Secretary | Jun 2008 |
Mr McBrayer has more than 30 years experience in nuclear medicine. He held the role of Managing Director at Lipa Pharmaceuticals, Australia's contract manufacturer of over the counter products and senior management positions with Brambles Cleanaway business and Syncor, the world's radioactive diagnostic and therapeutic pharmaceutical provider.
|
| Mathew Farag | Chief Operating Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Anglo Australian Christian and Charitable Fund | 13,211,332 | 14.15% |
| Barings Acceptance Limited | 11,444,962 | 12.26% |
| Hsbc Custody Nominees (Australia) Limited A/C 2 | 9,708,240 | 10.40% |
| National Nominees Limited | 9,533,466 | 10.21% |
| Chemical Overseas Limited | 8,005,769 | 8.57% |
| CVC Limited | 6,644,758 | 7.12% |
| Citicorp Nominees Pty Limited | 3,226,788 | 3.46% |
| CS Third Nominees Pty Limited <HSBC Cust Nom AU Ltd 13 AC> | 1,982,189 | 2.12% |
| McBrayer Reid Investments Pty Ltd LTIP 6 <McBrayer Clan Trust Ac> | 1,721,554 | 1.84% |
| Chemical Overseas Limited (i) | 1,182,239 | 1.27% |
| Phillips River Pty Ltd <GAT AC> | 1,038,914 | 1.11% |
| Lloyds & Casanove Investment Partners Ltd | 987,503 | 1.06% |
| CS Fourth Nominees Pty <HSBC Cust Nom AU Ltd 11 AC> | 972,281 | 1.04% |
| Mr James McBrayer | 861,728 | 0.92% |
| Mr James McBrayer (i) | 861,728 | 0.92% |
| South Seas Holdings Pty Limited | 686,538 | 0.74% |
| City & Westminster Limited | 556,327 | 0.60% |
| Mathew Farag <LTIP Account Holding 4> | 500,000 | 0.54% |
| McBrayer Reid Investments Pty Limited <McBrayer Clan LTIP 8 Ac> | 500,000 | 0.54% |
| Malackey Holdings Pty Ltd | 431,758 | 0.46% |